Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

(1,3)-β-D-glucan Based Diagnosis of Invasive Candida Infection Versus Culture Based Diagnosis in Patients With Severe Sepsis or Septic Shock

NCT02734550 is registered in ClinicalTrials.gov with Center for Sepsis Control and Care, Germany as lead sponsor.

NCT NCT02734550
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02734550 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
(1,3)-β-D-glucan Based Diagnosis of Invasive Candida Infection Versus Culture Based Diagnosis in Patients With Severe Sepsis or Septic Shock
Lead sponsor
Center for Sepsis Control and Care, Germany
Phase
Not applicable
Overall status
Completed
Start date
September 12, 2016
Completion date
September 17, 2019
Enrollment
342 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

septic shock, severe sepsis